About
Gibson Oncology acquired the Indenos to provide a noticeable positive impact on cancer patient’s lives in two critical areas. First, cancer resistance continues to emerge among almost all cancer patients whom initially responded to some form of treatment. Indenos were specifically designed to achieve high drug concentrations and remain within cancer cells for optimal anti-cancer activity, which reduces the chances that cancer cells’ can remove the anti-cancer drug to avoid its own destruction – thus, Indenos fight cancer resistance. Second, Indenos have a favorable side effect profile so that cancer patients experience a better quality of life during treatment with no grade 3 or 4 diarrhea and much less grade 3 and 4 neutropenia. They believe, therefore, that their goal of Being Tough on Cancer, not on Patients, can be achieved through these novel anti-cancer drugs, and their planned Phase II trials are well-positioned for treating resistant cancers in children and adults.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 1,038 investors are based in Miami, Florida, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Miami, US
Contact Information
Find more investors like Gibson
Search Investors